Adverum Biotechnologies (ADVM) Projected to Post Quarterly Earnings on Monday

Adverum Biotechnologies (NASDAQ:ADVM - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($1.29) per share for the quarter.

Adverum Biotechnologies Stock Down 6.0 %

ADVM traded down $0.29 during midday trading on Thursday, hitting $4.55. 61,484 shares of the company traded hands, compared to its average volume of 261,593. The company's 50-day moving average is $4.39 and its 200 day moving average is $5.93. Adverum Biotechnologies has a 52 week low of $3.52 and a 52 week high of $18.50. The firm has a market capitalization of $94.63 million, a PE ratio of -0.76 and a beta of 1.14.

Analyst Ratings Changes

A number of equities research analysts have commented on ADVM shares. StockNews.com cut shares of Adverum Biotechnologies from a "hold" rating to a "sell" rating in a research note on Thursday, December 19th. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Adverum Biotechnologies in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $27.83.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.